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Abstract
Objectives To determine the incidence of any and referable diabetic
retinopathy in people with type 2 diabetes mellitus attending an annual
screening service for retinopathy and whose first screening episode
indicated no evidence of retinopathy.
Design Retrospective four year analysis.
Setting Screenings at the community based Diabetic Retinopathy
Screening Service for Wales, United Kingdom.
Participants 57 199 people with type 2 diabetes mellitus, who were
diagnosed at age 30 years or older and who had no evidence of diabetic
retinopathy at their first screening event between 2005 and 2009. 49
763 (87%) had at least one further screening event within the study
period and were included in the analysis.
Main outcome measures Annual incidence and cumulative incidence
after four years of any and referable diabetic retinopathy. Relations
between available putative risk factors and the onset and progression
of retinopathy.
Results Cumulative incidence of any and referable retinopathy at four
years was 360.27 and 11.64 per 1000 people, respectively. From the
first to fourth year, the annual incidence of any retinopathy fell from
124.94 to 66.59 per 1000 people, compared with referable retinopathy,
which increased slightly from 2.02 to 3.54 per 1000 people. Incidence
of referable retinopathy was independently associated with known
duration of diabetes, age at diagnosis, and use of insulin treatment. For
participants needing insulin treatment with a duration of diabetes of 10
years or more, cumulative incidence of referable retinopathy at one and
four years was 9.61 and 30.99 per 1000 people, respectively.
Conclusions Our analysis supports the extension of the screening
interval for people with type 2 diabetes mellitus beyond the currently
recommended 12 months, with the possible exception of those with
diabetes duration of 10 years or more and on insulin treatment.
Introduction
Diabetic retinopathy remains amajor cause of visual impairment
and blindness in the United Kingdom,1 with its early detection
and timely treatment2-4 capable of reducing the risk of visual
loss. The evidence that screening for diabetic retinopathy is cost
effective5 6 has led to the establishment, over the past 20 years,
of several screening programmes at local, regional, and national
levels throughout the UK and elsewhere, varying in size, design,
and complexity.7 8
Various methods have been used to screen for diabetic
retinopathy, including ophthalmoscopy (direct and indirect);9
obtaining retinal images (for example, Polaroid images),9-11 35
mm transparencies,12 and more recently digital images with13 or
without mydriasis;14 15 as well as combining ophthalmoscopy
with retinal photography.16 17 In 1999, the National Screening
Committee for England and Wales recommended the use of
digital photography through dilated pupils to screen people for
diabetic retinopathy18 19 from the age of 12 years. A national
consensus protocol for grading and disease management, based
on annual screening,20 was also developed as part of the yearly
review for every person with diabetes. In 2003, the Diabetic
Retinopathy Screening Service for Wales was established and
is currently responsible for the annual screening of 150 000
people registered with diabetes mellitus in Wales (about 5% of
the population).
Despite the increase in diabetes mellitus worldwide,21 some
evidence has suggested a decline during the past few decades
in the prevalence and incidence of diabetic retinopathy,
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especially sight threatening retinopathy. This reduction is
attributed not only to improved care but also to the earlier
detection of both diabetes and diabetic retinopathy.22-24 Evidence
from screening programmes of relatively small numbers of
patients with type 2 diabetes has also suggested that an extension
of the screening interval—beyond the currently recommended
12 months—would be safe for those without evidence of
retinopathy at first screening.25-29 Such a change in policy could
substantially reduce heath service expenditure while allowing
reinvestment into the screening service. This reinvestment could
provide more frequent screening for people with early exudative
maculopathy and early diabetic retinopathy, and allow earlier
discharge of patients at the hospital eye service as a result of
more frequent follow-up being available at the screening service.
Our study reviewed data for a large population of people with
type 2 diabetes mellitus who had shown no evidence of diabetic
retinopathy at their first screen. We estimated the annual and
cumulative incidence of retinopathy over a four year period,
and explored the association between the development of
retinopathy and its putative risk factors.
Methods
Study population
Every person known to have diabetes mellitus over the age of
12 years and registered with a general practice in Wales must
be referred to the Diabetic Retinopathy Screening Service for
Wales by their doctor, apart from those excluded on medical
grounds (for example, those unable to attend screening owing
to infirmity or comorbidity)30 or those already attending hospital
based ophthalmology services because of retinopathy. Our four
year retrospective analysis included data for all patients
classified as having type 2 diabetes mellitus, diagnosed over
the age of 30 years, andwho attended screening between January
2005 and November 2009. Exclusion criteria included: a
diagnosis, on referral to the screening service, of type 1 diabetes
mellitus; a diagnosis of type 2 diabetes mellitus but at age
younger than 30 years; or no type of diabetes mellitus recorded
on the referral notification (predominantly from primary care).
Data were anonymised before undergoing statistical analysis.
Screening procedure
After registration with the Diabetic Retinopathy Screening
Service for Wales, each patient is invited to attend screening at
a location closest to them (with an appointment date and time).
Screening is undertaken at a variety of venues throughoutWales,
including general practice surgeries and local hospitals or
community centres. A trained healthcare assistant assesses
patients’ current visual acuity in both eyes (achieved with or
without glasses or with pinhole reading), using an illuminated
3 m Snellen chart. Tropicamide (1%) is then applied to each
eye, and after about 15 minutes, a trained photographer takes
two 45° digital retinal images per eye (one macular centred, and
one nasal field) using a non-mydriatic Canon DGi camera (with
a 30D or 40D camera back). The retinal images are transferred
to a central reading centre for grading. The photographers can
also take additional images of the retina, lens, or iris if deemed
necessary.
Diabetic retinopathy grading
Trained staff use a standardised protocol to grade diabetic
retinopathy, which is an enriched version of the English National
Screening Protocol,20 and take the worst grade for either eye as
the final grading level.We used the following grading categories
of retinopathy: none present, background, preproliferative or
proliferative, and maculopathy (based on surrogate markers
such as exudates within 1 disc diameter of the fovea).
For the statistical analysis, we defined referable retinopathy as
participants with preproliferative or proliferative retinopathy
(with or without maculopathy), or maculopathywith background
retinopathy. This category relates to those whowould, according
to guidelines, need referral to the hospital eye service for further
assessment or treatment. Digital retinal images were not
considered gradable if the retina of both eyes could not be
visualised adequately—that is, retinal vessels were not visible
within 1 disc diameter of the centre of the fovea and fine vessels
were not visible across the surface of the optic disc.
Ethical approval
We sought advice from the South East Wales research ethics
committee, as well as from the Cardiff and Vale University
Health Board (previously the Cardiff and Vale National Health
Service trust), the host organisation for the Diabetic Retinopathy
Screening Service for Wales, on behalf of the Welsh Assembly
Government. In their considered opinion, this study was a
service evaluation and therefore did not require ethical approval.
Individual patients provided written informed consent at each
screening event for their anonymised data to be used in research.
Statistical analysis
We used descriptive analyses to characterise the study
population and patterns of diabetic retinopathy, and used t tests
and χ2 tests to explore differences between patients without any
retinopathy and those who developed any, background, or
referable retinopathy. Parametric survival analysis with
covariates identified those factors associated with the
development of referable retinopathy.
The presence or absence of diabetic retinopathy was determined
after each screening event during the study period. Although
intended to occur annually, screening took place at variable
times during the four year period. For people who developed
retinopathy between two screening events, the time to
development lay between the two episodes, and therefore the
data were interval censored; for those who did not develop the
disorder by the final screening event, the data were right
censored. We therefore modelled the time to development of
retinopathy using survival analysis to allow for these two types
of censoring.
We used a parametric approach, implemented by the routine
INTCENS program in Stata. From the estimated parameters,
the survival function was calculated to derive the annual and
cumulative incidence of any and referable diabetic retinopathy.
We used bootstrapping to calculate confidence intervals, because
we could not obtain the standard errors easily.31 Different
distributions were considered for the underlying survival times,
including Weibull, exponential, Gompertz, log normal, and
inverse Gaussian. We chose the distribution on the basis of the
Akaike information criterion.32
We explored the effect of putative risk factors with available
information (that is, age, sex, age at diagnosis, duration of
diabetes mellitus, and treatment types) by incorporating them
into this survival analysis. To avoid assumptions of linearity,
we used the following categories for the duration of diabetes:
less than five years, five to nine years, and 10 years or more.
Age categories were: 30-49 years, 50-59 years, and 70 years or
older. The risk factors were examined individually and then
re-examined in a multivariate analysis with all variables
included.We did statistical analyses using SPSS version 16 and
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Stata version 10; evidence of significance was taken as P<0.05
unless otherwise stated.
Results
A total of 85 214 individuals with type 2 diabetes mellitus
underwent screening for diabetic retinopathy between January
2005 and November 2009; 57 199 (67.1%) had no evidence of
retinopathy and were therefore eligible for inclusion in this
study. At the initial screening event, 22 501 (26.4%) had
evidence of background retinopathy and 3723 (4.4%) had
referable retinopathy. Those with referable retinopathy consisted
of: 1169 (1.4%) with maculopathy, 1279 (1.5%) preproliferative
retinopathy, and 262 (0.3%) proliferative retinopathy (817
(1.0%) preproliferative retinopathy andmaculopathy, 196 (0.2%)
proliferative retinopathy and maculopathy). We excluded 1791
(2.1%) participants who had images that could not be graded,
as well as those with evidence of existing retinopathy.
Of 57 199 people without evidence of diabetic retinopathy at
the first screening event, 7436 (13.0%) did not attend another
screening during the study period, 449 (6.0%) of whom were
not eligible for a second screen (which would have occurred
within 12 months). We do not know why the remaining 6987
(94.0%) people did not attend a second screening event, because
anonymisation of the records prevented further investigation;
however, this group was older and had a longer known duration
of diabetes than the group attending at least one additional
screening event (table 1⇓). We did not observe a significant
difference in the proportions of male participants between these
two groups.
We found that 49 763 participants had a second screening event,
31 924 (64.2%) a third, 10 615 (21.3%) a fourth, and 767 (1.5%)
a fifth (total of 93 069 events). Although screening was intended
to occur annually, the screening intervals were generally longer
than one year, with a mean (standard deviation) interval of 17.8
(6.3) months between the first and second screening events,
15.3 (4.4) months between the second and third, 13.2 (2.7)
months between the third and fourth, and 12.0 (1.9) months
between the fourth and fifth. Only 4479 (9%) participants had
an interval of 12 (1) months between screening events.
During the study, 12 922 (26.0%) participants with type 2
diabetes mellitus developed diabetic retinopathy, of whom the
vast majority (12 574 (97.3%)) developed background
retinopathy. Of 348 (0.7%) people who developed referable
retinopathy, 197 (56.6%) had evidence of maculopathy, 107
(30.7%) had preproliferative retinopathy, and 25 (7.2%)
proliferative retinopathy. Sixteen (4.6%) people had
preproliferative retinopathy andmaculopathy, and three (0.9%)
had proliferative retinopathy and maculopathy.
Of 28 participants who developed proliferative diabetic
retinopathy (with or without maculopathy), 14 (50.0%) did so
between 12 and 24 months after the first screening event, three
(10.7%) after 24-36 months, 10 (35.7%) after 36-48 months,
and one (3.6%) after 48 months. Duration of diabetes was less
than five years in 19 (68%) participants, and 27 (96%) received
diet and oral treatment, with only one receiving insulin. Of
participants who developed proliferative retinopathy within 12
to 24 months, none were on insulin treatment and only two
(14%) had had diabetes longer than 10 years.
In the survival analysis, we selected the Weibull distribution as
best fitting the data. Tables 2⇓ and 3⇓ show the estimated annual
and cumulative incidence of any and referable diabetic
retinopathy. The annual incidence of any retinopathy at one
year was 124.94 per 1000 people, decreasing to 66.59 per 1000
at four years, with a cumulative incidence of 360.27 per 1000
people at four years. By contrast, the annual incidence of
referable retinopathy increased from 2.02 to 3.54 per 1000
people, with a cumulative incidence of 11.64 at four years. The
cumulative incidence of each retinopathy group was about twice
as high in participants who received insulin treatment (tables 2
and 3).
Table 4⇓ summarises the baseline characteristics of the three
groups according to outcome—that is, participants who did not
develop diabetic retinopathy and those who developed any or
referable retinopathy. The mean known duration of diabetes
mellitus and the proportion of participants requiring insulin
treatment were significantly greater in those who developed
referable retinopathy than in those who remained free of
retinopathy. Mean ages at diagnosis of diabetes and at first
screening were lowest in the group that developed referable
retinopathy and highest in the group that did not develop any
retinopathy. Sex distribution did not differ between the groups.
Table 5⇓ shows the effects of putative risk factors on the risk
of participants developing diabetic retinopathy. A significantly
raised risk of referable retinopathy was associated with an
increased duration of diabetes mellitus. Risk was highest in
participants diagnosed at age 30-49 years, with significantly
reduced risks in those aged up to 70 years at diagnosis. The risk
of any or referable retinopathy varied greatly between different
types of diabetes treatment. Age, duration of diabetes, and
treatment had similar effects on the risk of developing
background retinopathy, although age at diagnosis of more than
70 years was associated with a significantly increased risk.
The incidence of referable retinopathy varied considerably
between subgroups. For example, for participants given diet
treatment only with a known duration of diabetes of less than
five years, the cumulative incidence of retinopathy at one, two,
and three years from the first negative screen was 1.83, 3.66,
and 5.45 per 1000 people, respectively. Corresponding values
for participants receiving insulin treatment with a duration of
diabetes of less than 10 years were 0.71, 3.80, and 10.10 per
1000 people, respectively. For participants with a duration of
diabetes of 10 years or more, the use of insulin treatment
increased cumulative incidence greatly (with insulin treatment
2.24, 5.86, and 10.33 per 1000 people; without insulin treatment
9.61, 17.10, and 24.26 per 1000 people).
Discussion
In our study relating to people with type 2 diabetes mellitus
enrolled in the national Diabetic Retinopathy Screening Service
for Wales from 2005 to 2009 with no evidence of diabetic
retinopathy at initial screening, the annual incidence of any
retinopathy per 1000 people was 124.94 (12.5%) in the first
year, falling each year to 66.59 (6.7%) in the fourth year. The
cumulative incidence at four years was 360.27 per 1000 people
(36.0%). The annual incidence of referable retinopathy per 1000
people was low at 2.02 (0.2%) in the first year, with a small
increase to 3.54 (0.4%) in the fourth year; the cumulative
incidence at four years was 11.64 (1.2%).
The incidence of referable retinopathy was positively and
independently associated with the known duration of type 2
diabetes and the need for insulin treatment, and inversely related
to age at diagnosis. For participants on diet treatment with a
duration of diabetes of less than five years, the cumulative
incidence of referable diabetic retinopathy at one, two, and three
years was 1.83, 3.66, and 5.45 per 1000 people, respectively.
By contrast, the corresponding values for participants using
insulin treatment with a duration of diabetes of more than 10
years were 9.61, 17.10, and 24.26 per 1000 people, respectively,
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an approximately fivefold increase. For participants not using
insulin with a duration of diabetes of more than 10 years, the
corresponding values were 2.24, 5.86, and 10.33 per 1000
people, respectively, and 0.71, 3.80, and 10.10 per 1000 people,
respectively, for those using insulin treatment with a duration
of diabetes of less than 10 years.
The results suggest that for people with type 2 diabetes mellitus
and no evidence of retinopathy at screening, the interval of
screening could be extended beyond the 12 months currently
(but rarely) adopted. Patients on insulin treatment with a history
of diabetes of 10 years or more should continue to be screened
annually.
Strengths and weaknesses of the study
The large sample size was one of the main strengths of this
study. Furthermore, all participants were screened for the
presence of retinopathy by a standardised protocol of digital
retinal imaging and subsequent grading by trained staff.
However, screening was restricted to two 45° retinal images
per eye, and only limited information was available on putative
risk factors for the development of diabetic retinopathy (we
could not obtain measures of glycaemic control, blood pressure,
and lipid concentrations).We recorded a high dropout rate (12%)
of participants who did not have a second screening event
despite being eligible. We were not able to obtain information
for those people who did not participate in screening; somemay
have been excluded for medical reasons, because they were
already receiving care from an ophthalmologist for diabetic
retinopathy, or they did not attend for other unknown reasons.
Comparison with other studies
The annual incidence of referable diabetic retinopathy observed
in our study was similar to that previously reported by Younis
and colleagues from the Liverpool Diabetic Eye screening
programme for sight threatening retinopathy (equivalent to our
category of referable retinopathy)—0.2% in the first year, with
a cumulative incidence of 1.7% at four years.26 The authors
recommended an extension of the screening interval to triennial
screening, based on the 95% probability of people remaining
free from sight threatening retinopathy with a mean screening
interval of 5.4 years.
Data from the annual screening programme in Norfolk28 and
the biennial screening programme in Iceland25 also concluded
that biennial screening intervals would be safe in those people
without evidence of diabetic retinopathy at screening. The
Icelandic screening programme reported that people who
developed sight threatening retinopathy were placed on annual
screening once they were identified as having background
retinopathy. Therefore, these patients had no undue delay in the
diagnosis or treatment of sight threatening retinopathy over the
10 year period of observation.25
A study of the Swedish screening programme used a three year
screening interval in a cohort of well controlled participants
(mean HbA1c 6.4% at baseline) with type 2 diabetes mellitus,
who showed no evidence of retinopathy and had a mean known
duration of diabetes of six years.29 The researchers observed
that 28% of participants developedmild tomoderate retinopathy,
but did not develop sight threatening or referable retinopathy
in the form of severe preproliferative or proliferative retinopathy
during the three year study period. However, they did identify
macular oedema in three people, one of whom needed laser
treatment.
Several studies, including the Liverpool Diabetic Eye Study,26
similarly found that the incidence of diabetic retinopathy was
associated with the duration of diabetes and the use of insulin
treatment.33-36 A younger age at diagnosis of diabetes has also
been linked with increased incidence of retinopathy,33 although
this association was not found in the UK Prospective Diabetes
Study.37 In agreement with previous studies,26 37 we found no
relation between the incidence of retinopathy and participants’
sex, but we found a strong association between incidence and
the use of insulin treatment, presumably indicating the stage of
the disease.
Therefore, on the present evidence, annual screening is not
necessary for people with type 2 diabetes with no lesions of
diabetic retinopathy seen on digital images. Exceptions would
include people with a duration of diabetes of 10 years or more
and on insulin treatment, who should be retained on annual
screening. If the screening service used a screening interval
longer than 1 year, it would need to use safeguards to ensure
that if patients changed risk groups within the year, a new
appropriate interval would apply. Safeguards would include the
education of patients and professionals to be aware of signs or
symptoms suggestive of sight threatening retinopathy, and robust
communication between healthcare professionals and the
screening service. As electronic patient records become more
widespread, these objectives could be more readily achievable.
Not all people classified as having referable diabetic retinopathy,
for the purpose of screening, need urgent treatment at the first
ophthalmological review. This is because most of these referrals
are for isolated exudates (exudative maculopathy) without
associated leakage (macular oedema) and early preproliferative
retinopathy that need further investigations with fluorescein
angiography or optical coherence tomography to determine high
risk features. Laser treatment for such changes is not indicated,
according to the Early Treatment of Diabetic Retinopathy
Study,3 although focal laser treatment is considered for clinically
important macular oedema. Early preproliferative retinopathy
is also generally not treated in the first instance, since such cases
are monitored for progression to high risk features and
sometimes these retinal signs can resolve with improvement of
glycaemic control.
The decision to treat is based on various factors, such as severity
and status of the fellow eye, diabetes control, blood pressure,
and lipid status. Clearly, if proliferative diabetic retinopathy is
evident, early treatment with pan retinal photocoagulation can
prevent the loss of vision.2A delay in diagnosing early exudative
maculopathy or preproliferative retinopathy should not
necessarily result in a poor outcome, since most diagnosed
patients would enter a period of observation by the
ophthalmologist after referral.
Future research
Our future research will explore the implications of varying the
screening interval using risk stratification. To better predict the
development of retinopathy, further research should investigate
additional risk factors (for example, the individual and collective
effects of glycaemic control (HbA1c), blood pressure, albumin
excretion, and lipid status, as well as possible treatments). These
findings could improve risk stratification by better defining safe
screening intervals on an individual basis. Another important
area to investigate further includes the economic effect of the
different screening intervals.
Conclusion and implications for policy
makers
Other screening programmes have been able to revise their
screening intervals based on evidence—that is, cervical,38
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breast,39 and bowel40 screening programmes in the UK. The
original recommendation to undertake annual screening for
diabetic retinopathy was based on a consensus view of experts
and the over-riding wish to include such findings as part of the
annual review for people with diabetes. Much debate has
surrounded the appropriate screening interval for retinopathy
screening, and although the American Diabetes Association
recently recommended yearly screening, it suggested less
frequent screening in people with at least one previous negative
screen.41
Our study shows that the annual incidence of referable diabetic
retinopathy is low in people with type 2 diabetes mellitus and
without evidence of retinopathy at initial screening. These results
lend further support to the suggestion of an extension to the
screening interval beyond the 12 months currently adopted
(although rarely achieved), with the possible exception of
patients with a known duration of diabetes of longer than 10
years and on insulin treatment, who should continue to be
screened annually. People who develop background retinopathy
should also continue annual screening to avoid any delay in
referral to ophthalmology services should sight threatening
retinopathy develop, as adopted by the Icelandic screening
service.25
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What is already known on this topic
Screening for diabetic retinopathy is cost effective
Diabetic retinopathy remains the leading cause of blindness in the working age population
Previous studies have questioned the need for annual screening
What this study adds
For people with type 2 diabetes mellitus with no evidence of diabetic retinopathy at initial screening, the interval of screening could be
extended beyond the 12 months currently adopted, but rarely achieved. Possible exceptions are patients with a history of diabetes of
10 years or more and on insulin treatment, who should continue to be screened annually
Future research should focus on a more comprehensive risk stratification as a basis for defining safe screening intervals
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Tables
Table 1| Baseline characteristics of study participants
P
Participants without evidence of diabetic retinopathy at initial screening
Characteristics
Attended at least one further screening event
(n=49 763)
Did not attend a further screening event
(n=6897)*
<0.00164.4 (11.3)66.9 (13.5)Age (years)†
<0.0014.2 (4.4)4.6 (4.8)Known duration of diabetes mellitus
(years)†
<0.00160.2 (11.3)62.3 (13.2)Age at diagnosis of diabetes mellitus
(years)†
Sex‡
0.08727 529 (55.3)3794 (55.0)Male
21 975 (44.2)3175 (46.0)Female
259 (0.5)18 (0.3)Unknown
Treatment for diabetes mellitus‡
<0.00117 236 (34.6)2684 (38.9)Diet
29 049 (58.4)3787 (54.9)Oral hypoglycaemic agents
2669 (5.4)394 (5.7)Insulin
809 (1.6)122 (1.8)Unknown
*Group includes eligible participants only. †Mean (standard deviation). ‡Number (%).
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Table 2| Yearly incidence of any and referable diabetic retinopathy in participants without retinopathy at baseline
Referable retinopathyAny retinopathyTime from last negative
screen Cumulative incidenceAnnual incidenceCumulative incidenceAnnual incidence
2.02 (1.63 to 2.44)2.02 (1.63 to 2.44)124.94 (120.62 to 128.32)124.94 (120.62 to 128.32)1 year
4.85 (4.29 to 5.43)2.82 (2.51 to 3.12)216.81 (211.50 to 220.04)91.68 (89.67 to 93.66)2 years
8.09 (7.20 to 8.93)3.24 (2.76 to 3.68)293.80 (287.34 to 297.76)76.96 (74.96 to 79.30)3 years
11.64 (10.27 to 13.00)3.54 (2.89 to 4.21)360.27 (352.98 to 366.06)66.59 (64.67 to 68.92)4 years
Data are incidence (95% confidence interval) per 1000 people. Incidence of background retinopathy is the difference between the incidences of any and referable
retinopathy.
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Table 3| Yearly incidence of any and referable diabetic retinopathy in participants using insulin treatment and without retinopathy at baseline
Referable retinopathyAny retinopathyTime from last negative
screen Cumulative incidenceAnnual incidenceCumulative incidenceAnnual incidence
2.56 (1.13 to 4.70)2.56 (1.13 to 4.70)192.43 (177.70 to 206.50)192.43 (177.70 to 206.50)1 year
7.67 (4.78 to 10.71)5.00 (3.33 to 6.50)320.64 (304.86 to 334.53)128.03 (120.00 to 136.85)2 years
14.48 (9.68 to 18.66)6.84 (4.23 to 9.43)421.62 (403.10 to 437.67)100.19 (92.02 to 109.50)3 years
22.81 (15.20 to 30.30)8.41 (4.40 to 12.90)502.95 (482.26 to 525.51)81.69 (74.32 to 89.49)4 years
Data are incidence (95% confidence interval) per 1000 people. Incidence of background retinopathy is the difference between the incidences of any and referable
retinopathy.
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Table 4| Baseline characteristics of participants according to outcome
PReferable retinopathy (n=348)PAny retinopathy (n=12 922)No retinopathy (n=36 841)*
0.00562.9 (11.3)0.00264.9 (11.3)64.2 (11.3)Age (years)†
<0.0015.6 (5.4)<0.0015.1 (4.9)3.9 (4.2)Known duration of diabetes mellitus (years)†
<0.00157.3 (11.8)<0.00159.8 (11.5)60.3 (11.3)Age at diagnosis of diabetes mellitus (years)†
Sex‡
0.786195 (56.2)0.2327183 (55.9)20 346 (55.5)Male
152 (43.8)5659 (44.1)16 316 (44.5)Female
Treatment for diabetes mellitus‡
<0.00172 (20.7)<0.0013318 (26.0)13 918 (38.5)Diet
234 (67.2)8326 (64.4)20 723 (57.3)Oral hypoglycaemic agents
42 (12.1)1114 (8.6)1555 (4.3)Insulin
*Reference group. †Mean (standard deviation). ‡Number (%).
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Table 5| Parametric survival analysis with covariates in participants who developed diabetic retinopathy, according to grading category
Referable retinopathyBackground retinopathyAny retinopathy
Putative risk
factor
Adjusted hazard
ratio (95% CI)
Crude hazard ratio
(95% CI)
Adjusted hazard
ratio (95% CI)
Crude hazard ratio
(95% CI)
Adjusted hazard
ratio (95% CI)
Crude hazard ratio
(95% CI)
Known duration of diabetes mellitus
1.001.001.001.001.001.00<5 years
1.35 (1.05 to 1.73)1.54 (1.21 to 1.96)1.29 (1.23 to 1.34)1.39 (1.34 to 1.45)1.29 (1.23 to 1.34)1.39 (1.34 to 1.45)5-9 years
1.61 (1.19 to 2.19)1.99 (1.49 to 2.66)1.67 (1.58 to 1.76)1.82 (1.73 to 1.92)1.68 (1.59 to 1.77)1.92 (1.74 to 1.93)≥10 years
Age at diagnosis
1.001.001.001.001.001.0030-49 years
0.75 (0.57 to 0.99)0.71 (0.54 to 0.94)0.97 (0.92 to 1.02)0.94 (0.89 to 0.99)0.97 (0.92 to 1.02)0.93 (0.89 to 0.98)50-59 years
0.57 (0.42 to 0.77)0.50 (0.37 to 0.67)1.00 (0.95 to 1.06)0.91 (0.87 to 0.96)0.99 (0.94 to 1.05)0.90 (0.86 to 0.95)60-69 years
0.83 (0.60 to 1.16)0.64 (0.47 to 0.88)1.20 (1.13 to 1.27)0.98 (0.93 to 1.04)1.20 (1.13 to 1.27)0.98 (0.03 to 1.03)≥70 years
Treatment for diabetes mellitus
1.001.001.001.001.001.00Diet
1.61 (1.22 to 2.12)1.78 (1.36 to 2.32)1.42 (1.36 to 1.48)1.48 (1.43 to 1.55)1.41 (1.36 to 1.47)1.48 (1.43 to 1.55)Oral
hypoglycaemic
agents
2.60 (1.73 to 3.90)3.39 (2.32 to 4.97)2.03 (1.89 to 2.18)2.34 (2.19 to 2.51)2.03 (1.89 to 2.18)2.35 (2.19 to 2.51)Insulin
All factors were significant at P<0.001.
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